School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK; Blood-borne Viruses and Sexually Transmitted Infections Section, Health Protection Scotland, Glasgow, UK.
Blood-borne Viruses and Sexually Transmitted Infections Section, Health Protection Scotland, Glasgow, UK; School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK.
Int J Drug Policy. 2018 Feb;52:115-122. doi: 10.1016/j.drugpo.2017.12.014.
BACKGROUND & AIMS: Although people who inject drugs (PWID) are at greatest risk of hepatitis C (HCV), treatment uptake in this population has historically been low. Highly effective direct acting antiviral (DAA) treatments for HCV have recently become available. Our aim was to assess the awareness among PWID of these new therapies and their effectiveness.
A national survey of PWID attending injecting equipment provision sites in Scotland during 2015-2016 included questions to gauge the awareness in this population of antiviral treatment and the high cure rates associated with new therapies (defined here as >80%).
Among 2623 PWID, 92% had ever been tested for HCV. After excluding those ever treated for HCV (n = 226), 79% were aware of HCV treatment. Awareness was more likely among those who had ever been tested and self-reported either a positive (adjusted odds ratio: 16.04, 95%CI 10.57-24.33) or negative (3.11, 2.30-4.22) test result, compared to those who were never tested. The minority of all respondents (17%) were aware of high cure rates. This awareness was more likely among those who had ever been in HCV specialist care (9.76, 5.13-18.60) and those who had not been in specialist care but had been tested and self-reported either a positive (3.91, 2.20-7.53) or negative (2.55, 1.35-4.81) test result, compared to those who had never been tested.
We found poor awareness of the high cure rates associated with DAAs among PWID in Scotland, despite relatively high rates of HCV testing in this population. Increased effort is needed to ensure population groups with high risk of HCV infection are fully informed of the highly effective antiviral medications now available to treat this chronic disease.
虽然注射毒品者（PWID）面临最大的丙型肝炎（HCV）风险，但该人群的治疗率历来较低。最近，出现了高效的直接作用抗病毒（DAA）治疗方法，用于治疗 HCV。我们旨在评估 PWID 对这些新疗法的认识及其疗效。
2015-2016 年期间，在苏格兰接受注射设备供应点服务的 PWID 参与了一项全国性调查，其中包含了一些问题，旨在评估这一人群对抗病毒治疗的认识以及新疗法（此处定义为>80%）的高治愈率。
在 2623 名 PWID 中，92%的人曾接受过 HCV 检测。排除曾接受过 HCV 治疗的人（n=226）后，79%的人知晓 HCV 治疗。曾接受过 HCV 检测并自述 HCV 检测结果阳性（调整后的优势比：16.04，95%CI 10.57-24.33）或阴性（3.11，2.30-4.22）的人，比从未接受过 HCV 检测的人更有可能知晓 HCV 治疗。所有受访者中只有少数（17%）知晓高治愈率。在曾接受过 HCV 专科治疗的人群（9.76，5.13-18.60）和未曾接受过专科治疗但接受过 HCV 检测且自述 HCV 检测结果阳性（3.91，2.20-7.53）或阴性（2.55，1.35-4.81）的人群中，知晓高治愈率的可能性更大，而那些从未接受过 HCV 检测的人则不然。
尽管苏格兰的 PWID 人群中 HCV 检测率相对较高，但我们发现他们对 DAA 相关的高治愈率认知程度较低。需要加大力度，确保 HCV 感染高危人群充分了解目前可用于治疗这种慢性疾病的高效抗病毒药物。
